Clinical Trial Detail

NCT ID NCT02089334
Title Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Rexahn Pharmaceuticals, Inc.
Indications

renal cell carcinoma

Therapies

Everolimus + RX-0201

Everolimus

Age Groups: adult

No variant requirements are available.